Appendiceal Neoplasms clinical trials
The registry lists 86 studies for Appendiceal Neoplasms across more than 10 countries. 25 are recruiting or about to start. 28 of them are mainly about Appendiceal Neoplasms (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-10.
Get an email when these change. Save the Appendiceal Neoplasms studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
National Cancer Institute (NCI) (9) · Wake Forest University Health Sciences (6) · M.D. Anderson Cancer Center (3) · City of Hope Medical Center (3) · Memorial Sloan Kettering Cancer Center (3) · Dartmouth-Hitchcock Medical Center (3) · Case Comprehensive Cancer Center (2) · Revolution Medicines, Inc. (2)
What is being tested here
Drugs under test in Appendiceal Neoplasms studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Mitomycin | 4 | 1 | 8 |
| Oxaliplatin | 2 | 0 | 10 |
| Fluorouracil | 2 | 0 | 4 |
| Cisplatin | 2 | 0 | 3 |
| Doxorubicin | 2 | 0 | 2 |
| Irinotecan | 1 | 0 | 6 |
| Leucovorin | 1 | 0 | 2 |
| Elironrasib | 1 | 0 | 2 |
| Melphalan | 1 | 0 | 2 |
| KRAS G12D Inhibitor VS-7375 | 1 | 0 | 1 |
Drug classes tested here Alkylating agents 5 open · Antimetabolites 2 open · Tyrosine kinase inhibitors (TKIs) 1 open
Coming up
9studies finish main data collection within a year
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
All 9
- Jan 2027Molecular Profiling for Risk Stratification in Appendiceal Cancer · City of Hope Medical Center
- Jan 2027Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes · Cedars-Sinai Medical Center
- Mar 2027Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors · Revolution Medicines, Inc.
- Aug 2027Intraoperative Imaging of Gastrointestinal Malignancies Using Pafolacianine (CYTALUX™) · Cedars-Sinai Medical Center
- Sep 2027ICARuS Post-operative Intraperitoneal Chemotherapy (EPIC) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) After Optimal Cytoreductive Surgery (CRS) for Neoplasms of the Appendix, Colon or Rectum With Isolated Peritoneal Metastasis · Memorial Sloan Kettering Cancer Center
- Sep 2027Individualized Dose Escalation of 5-FU for Gastrointestinal Cancer · Dartmouth-Hitchcock Medical Center
- Sep 2027Target-specific immunoPET Imaging of Digestive System Carcinoma · RenJi Hospital
- Oct 2027A Feasibility Study of Mass-Based Response Drug Screening to Guide Personalized Hyperthermic Intraperitoneal Chemotherapy for High-Grade Appendiceal and Colorectal Adenocarcinoma With Peritoneal Metastasis · Yale University
- Oct 2027Plasma 5hmC Signatures as a Marker of Colorectal / Appendiceal Peritoneal Metastasis · University of Chicago
Who these studies take
Of the 24 Appendiceal Neoplasms studies recruiting now, 17 (71%) set no upper age limit and 4 (17%) stop at 75 or younger. 2 (8%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 2 (8%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 2 (8%) | 2 (8%) |
| 18 | 23 (96%) | 23 (96%) |
| 30 | 23 (96%) | 23 (96%) |
| 40 | 23 (96%) | 23 (96%) |
| 50 | 23 (96%) | 23 (96%) |
| 65 | 23 (96%) | 23 (96%) |
| 75 | 22 (92%) | 22 (92%) |
| 85 | 19 (79%) | 19 (79%) |
Across all 86 studies, recruiting or not: 6% stop at 75 or younger and 2% at 65; 13% take children; 0% are for women only and 0% for men only; 5% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
Studies
Recruiting first, then most recently updated. Showing 50 of 86. Browse all 86 → or search them.
- A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid TumorsRecruitingNCT07020221Phase 1/24 countries
- Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal HistologiesRecruitingNCT04847063Phase 11 country
- Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT TrialRecruitingNCT07271355Phase 31 country
- Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment DelaysRecruitingNCT07283939Not applicable3 countries
- NALIRIFOX (Nal-IRI Plus 5-FU/LV Plus Oxaliplatin) as First-Line Treatment for Patients With Advanced Small Intestine and Appendiceal CancersRecruitingNCT07060014Phase 11 country
- Intraoperative Imaging of Gastrointestinal Malignancies Using Pafolacianine (CYTALUX™)RecruitingNCT07124351Phase 41 country
- Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid TumorsRecruitingNCT06128551Phase 1/27 countries
- Safety and Efficacy of PIPAC Using Single Agent Mitomycin in Solid TumorsRecruitingNCT07487168Phase 11 country
- EQUITY GI: A Prospective Study to Enhance Quality, Inclusivity, and Trial Participation in Black Patients With Gastrointestinal Cancer.RecruitingNCT06263088Not applicable1 country
- PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric CancerRecruitingNCT04329494Phase 11 country
- The Appendix Cancer PMP Research Foundation Natural History Study/Patient RegistryRecruitingNCT077693461 country
- A Feasibility Study of Mass-Based Response Drug Screening to Guide Personalized Hyperthermic Intraperitoneal Chemotherapy for High-Grade Appendiceal and Colorectal Adenocarcinoma With Peritoneal MetastasisRecruitingNCT07291180Not applicable1 country
- Locally ablatIVe thErapy for oLigo-progressive gastrOintestiNal maliGnancies (LIVELONG)RecruitingNCT06101277Not applicable1 country
- Molecular Profiling for Risk Stratification in Appendiceal CancerRecruitingNCT075872681 country
- Individualized Dose Escalation of 5-FU for Gastrointestinal CancerRecruitingNCT05780684Not applicable1 country
- Technical Feasibility of Modified Early Post-Operative Intraperitoneal Chemotherapy (mEPIC)RecruitingNCT05913674Phase 21 country
- Flat Dose vs. Weight-based IP Chemotherapy for CRS/HIPECRecruitingNCT04779554Phase 21 country
- Virtual Reality for GI Cancer Pain to Improve Patient Reported OutcomesRecruitingNCT04907643Not applicable1 country
- Target-specific immunoPET Imaging of Digestive System CarcinomaRecruitingNCT06715839Not applicable1 country
- Surufatinib and Sintilimab in Combination With Capecitabine for Metastatic Adenocarcinoma of Small Intestine or Appendix CarcinomaRecruitingNCT05472948Phase 21 country
- Genetics of Appendix Cancer StudyRecruitingNCT057344301 country
- Molecular Characterisation of Appendiceal CancerRecruitingNCT053647881 country
- Value of Right-sided Hemicolectomy for Chldren With High-risk Neuroendocrine Tumors of the AppendixRecruitingNCT059197581 country
- Comparing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS-HIPEC) Using Mitomycin-C Versus Melphalan for Colorectal Peritoneal CarcinomatosisRecruitingNCT03073694Phase 21 country
- The Prevalence of Appendiceal Tumours in Periappendicular AbscessNot yet recruitingNCT04634448Not applicable
- ICARuS Post-operative Intraperitoneal Chemotherapy (EPIC) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) After Optimal Cytoreductive Surgery (CRS) for Neoplasms of the Appendix, Colon or Rectum With Isolated Peritoneal MetastasisActive, not recruitingNCT01815359Phase 21 country
- Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid TumorsCompletedNCT04902872Phase 1/21 country
- Intraperitoneal Aerosolized Nanoliposomal Irinotecan (Nal-IRI) in Peritoneal Carcinomatosis From Gastrointestinal CancerActive, not recruitingNCT05277766Phase 11 country
- Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal CarcinomatosisCompletedNCT05185947Phase 21 country
- Crossover Trial of Systemic Chemotherapy in Patients With Metastatic Well-Differentiated Mucinous Appendiceal Adenocarcinomas With Pseudomyxoma PeritoneiActive, not recruitingNCT01946854Not applicable1 country
- Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid TumorsActive, not recruitingNCT05462717Phase 113 countries
- Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)CompletedNCT054614301 country
- JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C MutationActive, not recruitingNCT05194995Phase 1/21 country
- Oral Cryotherapy Plus Acupressure and Acupuncture Versus Oral Cryotherapy for Decreasing Chemotherapy-Induced Peripheral Neuropathy From Oxaliplatin-Based Chemotherapy in Patients With Gastrointestinal CancerCompletedNCT04505553Phase 21 country
- Plasma 5hmC Signatures as a Marker of Colorectal / Appendiceal Peritoneal MetastasisActive, not recruitingNCT041573221 country
- Clinical Trial of a Novel Dose Adjustment Algorithm for Preventing Cytopenia-Related Delays During FOLFOX ChemotherapyCompletedNCT04526886Not applicable1 country
- Diagnostic Value of Diffusion-weighted Magnetic Resonance in High-risk Colorectal and Appendiceal NeoplasmsActive, not recruitingNCT05623787Not applicable1 country
- The Registry of Oncology Outcomes Associated with Testing and TreatmentCompletedNCT040284791 country
- Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to DrugsWithdrawnNCT04985357
- Antibiotic Treatment and Long-term Outcomes of Patients With Pseudomyxoma Peritonei of Appendiceal OriginActive, not recruitingNCT02387203Phase 21 country
- HIPEC for Peritoneal CarcinomatosisCompletedNCT02040142Phase 21 country
- Intraperitoneal LSTA1 in CRS-HIPECWithdrawnNCT06216561Phase 11 country
- Selective Rather Than Routine Histopathological Examination Following Appendectomy and CholecystectomyCompletedNCT035109231 country
- Perioperative Exercise and Nutritional Optimisation Prehabilitation Before Surgery for Patients With Peritoneal MalignancyActive, not recruitingNCT05305820Not applicable1 country
- Psychological, Psychophysical and Epigenetic Determinants of Chronic Pain After Cytoreductive - Hyperthermic Intraoperative ChemotherapyCompletedNCT050833381 country
- Severe Neutropenia After HIPEC Using Mitomycin-CCompletedNCT055131831 country
- Gastrointestinal Microbiome Study of Appendiceal CancerStatus unknownNCT02599116Not applicable1 country
- A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal MalignanciesCompletedNCT02963831Phase 1/21 country
- Programs To Support You During ChemotherapyCompletedNCT02489422Not applicable1 country
- LCI-GI-APX-NIN-001: Nintedanib in Metastatic Appendiceal CarcinomaTerminatedNCT03287947Phase 21 country